Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Background With the increase in the aging population worldwide, Alzheimer's disease has
become a rapidly increasing public health concern. Monitoring the dementia disease burden …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Ubiquitous yet unique, lipid droplets are intracellular organelles that are increasingly being
recognized for their versatility beyond energy storage. Advances uncovering the intricacies …

Latin American populations may present patterns of sociodemographic, ethnic and cultural
diversity that can defy current universal models of healthy aging. The potential combination …

Strong genetic evidence supports an imbalance between production and clearance of
amyloid β-protein (Aβ) in people with Alzheimer disease (AD). Microglia that are potentially …

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …